# Biotricity Inc.: financial statements, quarterly

BTCY · OTC · CIK 1630113 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/btcy.md) · [Financials](/companies/btcy/financials.md) · [Filings](/companies/btcy/filings.md) · [Insiders](/companies/btcy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/btcy/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [2,891](/filings/0001493152-24-046028.md) | [2,973](/filings/0001493152-25-007664.md) | [3,178 d](/filings/0001641172-25-020105.md) | [3,202](/filings/0001641172-25-023709.md) | [3,267](/filings/0001493152-25-023361.md) | [3,619](/filings/0001493152-26-006211.md) | [3,703 d](/filings/0001493152-26-033207.md) | [3,874](/filings/0001493152-26-039209.md) | [3,886](/filings/0001493152-25-023361.md) | [3,988](/filings/0001493152-26-006211.md) | [4,251 d](/filings/0001493152-26-033207.md) | [4,277](/filings/0001493152-26-039209.md) |
| Cost of revenue | $k | [892](/filings/0001493152-24-046028.md) | [805](/filings/0001493152-25-007664.md) | [906 d](/filings/0001641172-25-020105.md) | [839](/filings/0001641172-25-023709.md) | [808](/filings/0001493152-25-023361.md) | [855](/filings/0001493152-26-006211.md) | [724 d](/filings/0001493152-26-033207.md) | [757](/filings/0001493152-26-039209.md) | [704](/filings/0001493152-25-023361.md) | [736](/filings/0001493152-26-006211.md) | [852 d](/filings/0001493152-26-033207.md) | [746](/filings/0001493152-26-039209.md) |
| Gross profit | $k | [1,999](/filings/0001493152-24-046028.md) | [2,168](/filings/0001493152-25-007664.md) | [2,272 d](/filings/0001641172-25-020105.md) | [2,363](/filings/0001641172-25-023709.md) | [2,459](/filings/0001493152-25-023361.md) | [2,764](/filings/0001493152-26-006211.md) | [2,978 d](/filings/0001493152-26-033207.md) | [3,117](/filings/0001493152-26-039209.md) | [3,181](/filings/0001493152-25-023361.md) | [3,251](/filings/0001493152-26-006211.md) | [3,399 d](/filings/0001493152-26-033207.md) | [3,531](/filings/0001493152-26-039209.md) |
| Research and development | $k | [698](/filings/0001493152-24-046028.md) | [453](/filings/0001493152-25-007664.md) | [708 d](/filings/0001641172-25-020105.md) | [514](/filings/0001641172-25-023709.md) | [518](/filings/0001493152-25-023361.md) | [551](/filings/0001493152-26-006211.md) | [573 d](/filings/0001493152-26-033207.md) | [696](/filings/0001493152-26-039209.md) | [603](/filings/0001493152-25-023361.md) | [624](/filings/0001493152-26-006211.md) | [842 d](/filings/0001493152-26-033207.md) | [673](/filings/0001493152-26-039209.md) |
| Selling, general and administrative | $k | [3,487](/filings/0001493152-24-046028.md) | [2,997](/filings/0001493152-25-007664.md) | [4,608 d](/filings/0001641172-25-020105.md) | [2,966](/filings/0001641172-25-023709.md) | [2,249](/filings/0001493152-25-023361.md) | [2,382](/filings/0001493152-26-006211.md) | [3,261 d](/filings/0001493152-26-033207.md) | [2,139](/filings/0001493152-26-039209.md) | [2,305](/filings/0001493152-25-023361.md) | [2,187](/filings/0001493152-26-006211.md) | [1,863 d](/filings/0001493152-26-033207.md) | [2,699](/filings/0001493152-26-039209.md) |
| Operating income | $k | [(2,186)](/filings/0001493152-24-046028.md) | [(1,282)](/filings/0001493152-25-007664.md) | [(3,044) d](/filings/0001641172-25-020105.md) | [(1,117)](/filings/0001641172-25-023709.md) | [(308)](/filings/0001493152-25-023361.md) | [(169)](/filings/0001493152-26-006211.md) | [(855) d](/filings/0001493152-26-033207.md) | [282](/filings/0001493152-26-039209.md) | [274](/filings/0001493152-25-023361.md) | [441](/filings/0001493152-26-006211.md) | [695 d](/filings/0001493152-26-033207.md) | [158](/filings/0001493152-26-039209.md) |
| Interest expense | $k | [753](/filings/0001493152-24-046028.md) | [790](/filings/0001493152-25-007664.md) | [815 d](/filings/0001493152-24-025344.md) | [769](/filings/0001493152-24-033159.md) | [752](/filings/0001493152-24-046028.md) | [850](/filings/0001493152-25-007664.md) | [892 d](/filings/0001493152-26-033207.md) | [850](/filings/0001493152-26-039209.md) | [860](/filings/0001493152-25-023361.md) | [810](/filings/0001493152-26-006211.md) | [841 d](/filings/0001493152-26-033207.md) | [852](/filings/0001493152-26-039209.md) |
| Net income | $k | [(3,691)](/filings/0001493152-24-046028.md) | [(2,808)](/filings/0001493152-25-007664.md) | [(4,182) d](/filings/0001641172-25-020105.md) | [(3,695)](/filings/0001641172-25-023709.md) | [(1,562)](/filings/0001493152-25-023361.md) | [(1,229)](/filings/0001493152-26-006211.md) | [(1,936) d](/filings/0001493152-26-033207.md) | [(672)](/filings/0001493152-26-039209.md) | [(691)](/filings/0001493152-25-023361.md) | [(717)](/filings/0001493152-26-006211.md) | [(324) d](/filings/0001493152-26-033207.md) | [(959)](/filings/0001493152-26-039209.md) |
| Diluted EPS | $ per share | [(0.44)](/filings/0001493152-24-046028.md) | [(0.34)](/filings/0001493152-25-007664.md) | not reported | [(0.49)](/filings/0001641172-25-023709.md) | [(0.07)](/filings/0001493152-25-023361.md) | [(0.05)](/filings/0001493152-26-006211.md) | not reported | [(0.03)](/filings/0001493152-26-039209.md) | [(0.03)](/filings/0001493152-25-023361.md) | [(0.04)](/filings/0001493152-26-006211.md) | not reported | [(0.05)](/filings/0001493152-26-039209.md) |
| Basic EPS | $ per share | [(0.44)](/filings/0001493152-24-046028.md) | [(0.34)](/filings/0001493152-25-007664.md) | not reported | [(0.49)](/filings/0001641172-25-023709.md) | [(0.07)](/filings/0001493152-25-023361.md) | [(0.05)](/filings/0001493152-26-006211.md) | not reported | [(0.03)](/filings/0001493152-26-039209.md) | [(0.03)](/filings/0001493152-25-023361.md) | [(0.04)](/filings/0001493152-26-006211.md) | not reported | [(0.05)](/filings/0001493152-26-039209.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | period not labelled (2025-08-31) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.1](/filings/0001493152-24-007244.md) | [0.8](/filings/0001641172-25-020105.md) | [0.1](/filings/0001493152-24-033159.md) | [0.2](/filings/0001493152-24-046028.md) | [0.5](/filings/0001493152-25-007664.md) | [0.4](/filings/0001493152-26-033207.md) | [0.4](/filings/0001641172-25-023709.md) | not reported | [0.3](/filings/0001493152-25-023361.md) | [0.3](/filings/0001493152-26-006211.md) | [0.1](/filings/0001493152-26-039209.md) | [0.5](/filings/0001493152-26-039209.md) |
| Current assets | $m | [3.9](/filings/0001493152-24-007244.md) | [4.5](/filings/0001641172-25-020105.md) | [4.1](/filings/0001493152-24-033159.md) | [4.1](/filings/0001493152-24-046028.md) | [4.9](/filings/0001493152-25-007664.md) | [4.6](/filings/0001493152-26-033207.md) | [5.1](/filings/0001641172-25-023709.md) | not reported | [5.5](/filings/0001493152-25-023361.md) | [5.0](/filings/0001493152-26-006211.md) | [5.9](/filings/0001493152-26-039209.md) | [5.6](/filings/0001493152-26-039209.md) |
| Total assets | $m | [5.5](/filings/0001493152-24-007244.md) | [5.9](/filings/0001641172-25-020105.md) | [5.4](/filings/0001493152-24-033159.md) | [5.3](/filings/0001493152-24-046028.md) | [6.0](/filings/0001493152-25-007664.md) | [5.6](/filings/0001493152-26-033207.md) | [6.0](/filings/0001641172-25-023709.md) | not reported | [6.3](/filings/0001493152-25-023361.md) | [5.7](/filings/0001493152-26-006211.md) | [6.4](/filings/0001493152-26-039209.md) | [6.0](/filings/0001493152-26-039209.md) |
| Current liabilities | $m | [18.6](/filings/0001493152-24-007244.md) | [22.7](/filings/0001641172-25-020105.md) | [20.6](/filings/0001493152-24-033159.md) | [21.5](/filings/0001493152-24-046028.md) | [21.1](/filings/0001493152-25-007664.md) | [20.6](/filings/0001493152-26-033207.md) | [21.8](/filings/0001641172-25-023709.md) | not reported | [23.6](/filings/0001493152-25-023361.md) | [23.8](/filings/0001493152-26-006211.md) | [37.1](/filings/0001493152-26-039209.md) | [37.3](/filings/0001493152-26-039209.md) |
| Total liabilities | $m | [32.2](/filings/0001493152-24-007244.md) | [35.9](/filings/0001641172-25-020105.md) | [33.0](/filings/0001493152-24-033159.md) | [34.2](/filings/0001493152-24-046028.md) | [35.8](/filings/0001493152-25-007664.md) | [35.7](/filings/0001493152-26-033207.md) | [36.8](/filings/0001641172-25-023709.md) | not reported | [38.0](/filings/0001493152-25-023361.md) | [38.2](/filings/0001493152-26-006211.md) | [39.4](/filings/0001493152-26-039209.md) | [39.7](/filings/0001493152-26-039209.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [1.2](/filings/0001493152-26-006211.md) | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(27.8)](/filings/0001493152-25-007664.md) | [(31.5)](/filings/0001493152-26-033207.md) | [(29.8)](/filings/0001493152-25-023361.md) | [(31.2)](/filings/0001493152-26-006211.md) | [(31.9)](/filings/0001493152-26-006211.md) | [(32.0)](/filings/0001493152-26-039209.md) | [(32.8)](/filings/0001493152-26-039209.md) | not reported | [(33.4)](/filings/0001493152-26-006211.md) | [(34.2)](/filings/0001493152-26-006211.md) | [(34.7)](/filings/0001493152-26-039209.md) | [(35.4)](/filings/0001493152-26-039209.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,390) d](/filings/0001493152-24-046028.md) | [(1,306) d](/filings/0001493152-25-007664.md) | [(1,166) d](/filings/0001641172-25-020105.md) | [(1,494)](/filings/0001641172-25-023709.md) | [(397) d](/filings/0001493152-25-023361.md) | [(88.1) d](/filings/0001493152-26-006211.md) | [(401) d](/filings/0001493152-26-033207.md) | [(373)](/filings/0001493152-26-039209.md) | [416 d](/filings/0001493152-25-023361.md) | [(740) d](/filings/0001493152-26-006211.md) | [(20.9) d](/filings/0001493152-26-033207.md) | [507](/filings/0001493152-26-039209.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: not reported

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.6](/filings/0001493152-23-041243.md) | [8.7](/filings/0001493152-24-007244.md) | [8.8](/filings/0001493152-24-033159.md) | [8.8](/filings/0001493152-24-046028.md) | [9.0](/filings/0001493152-25-007664.md) | [14.2](/filings/0001641172-25-023709.md) | [22.5](/filings/0001493152-25-023361.md) | [24.2](/filings/0001493152-26-006211.md) | [26.3](/filings/0001493152-26-039209.md) | [26.8](/filings/0001493152-25-023361.md) | [27.6](/filings/0001493152-26-006211.md) | [23.1](/filings/0001493152-26-039209.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 19,914,003 at 2026-08-19, from the cover of the [10-Q filed 2026-08-19](/filings/0001493152-26-039209.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.